Navigation Links
Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
Date:5/2/2011

SAN DIEGO, May 2, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will report first quarter 2011 financial results on Thursday, May 5, 2011, after the U.S. financial markets close.

Anadys will hold a conference call and webcast on Thursday, May 5, 2011 at 5:00 p.m. Eastern Daylight Time to discuss its first quarter 2011 financial results and highlights and to provide an update on its development programs.  A live webcast of the call will be available online at www.anadyspharma.com.  A telephone replay will also be available approximately one hour after completion of the call.  To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 23621944.  The webcast and telephone replay will be available through May 19, 2011.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C.  The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines.  Anadys is conducting a Phase IIb study of ANA598, the Company's direct-acting antiviral or DAA, added to current standard of care for the treatment of hepatitis C.  The Company is also preparing to resume clinical development of ANA773, the Company's oral, small-molecule inducer of endogenous interferons that acts via the Toll like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements."  Such statements include, but are not limited to, references to Anadys' strategy, development
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2010 Financial Results and Highlights
2. Anadys Pharmaceuticals Augments Management Team and Board of Directors
3. Anadys Pharmaceuticals to Present at the Lazard Healthcare Conference
4. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2009 Financial Results
5. Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
6. Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
7. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
8. Anadys Pharmaceuticals, Inc. Announces Strategic Restructuring to Focus Operations on Continuing the Advancement of ANA598
9. Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
10. Anadys Pharmaceuticals to Report First Quarter 2009 Financial Results
11. Anadys Pharmaceuticals to Present at Future Leaders in the Biotech Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 27, 2015 Research and Markets( http://www.researchandmarkets.com/research/l9dqwt/animal_genetics ) ... Market by Products, by Testing services - Global Forecast ... The global animal genetics market is estimated to be ... a CAGR of 8-9% during the forecast period of ... driven by increasing animal protein consumption, increasing adoption of ...
(Date:5/28/2015)... Research and Markets( http://www.researchandmarkets.com/research/3nl6s2/neuroprotection ) has ... "Neuroprotection - Drugs, Markets and Companies" ... the role of neuroprotection in acute disorders such ... as well as in chronic diseases such as ... of damage to neural tissues are similar in ...
(Date:5/28/2015)... May 28, 2015 Celsion Corporation (the "Company") ... received commitments from two institutional healthcare investors to purchase ... common stock in an at-the-market registered direct offering and ... stock. The Company entered into a definitive ... Company agreed to sell an aggregate of 3,000,000 shares ...
(Date:5/28/2015)... 28, 2015 DryLet, LLC a ... applications such as animal waste reduction, bioremediation, wastewater ... in wastewater treatment plants and restaurant kitchen settings, ... Pork Expo, June 3-5 in Des Moines, Iowa. ... a Wall Street Journal article because of its ...
Breaking Biology Technology:Global Animal Genetics (Canine, Equine, Poultry, Porcine, Bovine, and Genetic Material) Market 2015 - Global Forecast to 2020 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 2Global Neuroprotection Market Report 2015-2024 - Drugs, Markets and Companies 3Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering 3DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2
... /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine ... 3-year research agreement with Defence Research and Development ... application of IVT,s DepoVax(TM) vaccine formulation to anthrax ... for, and respond to biological threats. , "Dr. ...
... from Colorectal Cancer and Oral Picoplatin Trials To Be ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... will present final data from two Phase 1 clinical ... poster sessions during the American Association for Cancer Research ...
... Zenobia Therapeutics, Inc., the leader in fragment-based lead ... announced successful completion of the first phase of ... subsidiary of Biogen Idec (Nasdaq: BIIB ... access to Zenobia,s technology and expertise in structural ...
Cached Biology Technology:ImmunoVaccine Technologies Collaborates with Defence Research & Development Canada to Strengthen Canada's Ability to Deal with Biological Threats 2Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting 2Zenobia Therapeutics Successfully Completes Initial Phase of Its Service Agreement With Syntonix Pharmaceuticals 2
(Date:5/22/2015)... OXFORD, CT , May 22, 2015  NXT-ID, Inc. ... from June 1st, it will be ending its promotional pricing ... www.wocketwallet.com . Laurence Savin , Head of ... our exclusive promotional pricing until the end of May. To ... at wocketwallet.com/invite and when we open the store on June ...
(Date:5/21/2015)... 21, 2015 According to ... Solutions (Hardware, Software, Services), by Applications (Surveillance (Airborne, ... by End-Users (Military & Defense & Commercial) - ... Imaging Market is expected to grow from $7252.0 ... at a Compound Annual Growth Rate (CAGR) of ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
Breaking Biology News(10 mins):NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 2NXT-ID, Inc Announces Retail Price For Wocket Smart Wallet And Extends Discounted Promotional Price Till End Of May 3Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2
... hosting a lecture and symposium Tuesday, March 10, through ... disastrous floods of summer 2008. "Living With Floods: ... symposium in The Forkenbrock Series on Public Policy. National ... floods to the psychological impact of displacement, from flood ...
... infection by intestinal worms a condition that affects more ... the immune system is more versatile than has long been ... of exploration in the search for treatments against autoimmune diseases ... own tissues. The findings, reported by scientists who performed ...
... about how to "grow your own organs" using stem cells ... has been elusive. A new report published in the March ... ) brings bioengineered organs a step closer, as scientists from ... they were able to use a "scaffolding" material extracted from ...
Cached Biology News:Public Policy Center hosts flood symposium March 10-12 2A worm-and-mouse tale: B cells deserve more respect 2A worm-and-mouse tale: B cells deserve more respect 3From stem cells to new organs: Stanford and NYU scientists cross threshold in regenerative medicine 2
Rabbit polyclonal to JAK1 (phospho Y1022 + Y1023) ( Abpromise for all tested applications). entrezGeneID: 3716 SwissProtID: P23458...
Complete PCR kit. Includes: MasterAmp™ Taq DNA Polymerase, 10X PCR Buffer, MasterAmp™ 10X PCR Enhancer, dNTP Mix, 2.5 mM each, 25 mM MgCl2, Enzyme Dilution Buffer, Control Template and Prim...
Request Info...
The FailSafe™ PROBES Real-Time PCR System enables rapid, precise optimization of PCR experiments in which the product is detected using fluorescent target-specific labeled probes....
Biology Products: